Close

pCDCAR1 EGFR h(28ζ) (CAR-ZP8038)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Melanoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFR
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Melanoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 7B3
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 FACS analysis demonstrated the binding of scFv-M27-Fc, scFv-806-Fc, and scFv-C225-Fc to the indicated target cells.

CAR Construction : Latest CAR Construction

Fig.1 FACS analysis demonstrated the binding of scFv-M27-Fc, scFv-806-Fc, and scFv-C225-Fc to the indicated target cells.

Fluorescence was assessed by using a BD FACSCelesta flow cytometer.

Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., ... & Li, Z. (2018). Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research, 6(11), 1314-1326.

Complete CAR data FCM

Fig.2 Characterization of EGFR/EGFRvIII bitargeted CAR T cells.

CAR Construction : 7B3 scFv-28ζ Latest CAR Construction

Fig.2 Characterization of EGFR/EGFRvIII bitargeted CAR T cells.

Expression of EGFR-specific CARs on the lentivirus-transduced human T cells was analyzed using flow cytometry.

Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., ... & Li, Z. (2018). Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research, 6(11), 1314-1326.

Complete CAR data Cyt

Fig.3 In vitro cytotoxic activities of EGFR/EGFRvIII-targeted CAR T cells.

CAR Construction : 7B3 scFv-28ζ Latest CAR Construction

Fig.3 In vitro cytotoxic activities of EGFR/EGFRvIII-targeted CAR T cells.

Primary human T cells transduced with the indicated lentiviral vectors were incubated with the untransfected and transfected glioblastoma cells at
the various E:T ratios for 18 hours.

Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., ... & Li, Z. (2018). Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research, 6(11), 1314-1326.

Complete CAR data FuncS

Fig.4 In vivo antitumor activities of M27-28BBZ CAR T cells on established subcutaneous EGFR- or EGFRvIII-overexpressing glioblastoma xenografts.

CAR Construction : 7B3 scFv-28ζ Latest CAR Construction

Fig.4 In vivo antitumor activities of M27-28BBZ CAR T cells on established subcutaneous EGFR- or EGFRvIII-overexpressing glioblastoma xenografts.

Data are presented as the mean tumor volume ± SEM.

Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., ... & Li, Z. (2018). Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research, 6(11), 1314-1326.

Complete CAR data FuncS

Fig.5 The persistence of human T cells from mice treated with the indicated genetically modified T cells in orthotopic glioblastoma xenografts models.

CAR Construction : 7B3 scFv-28ζ Latest CAR Construction

Fig.5 The persistence of human T cells from mice treated with the indicated genetically modified T cells in orthotopic glioblastoma xenografts models.

The representative immunostaining images of CD3þ T-cell infiltration in tumor-bearing mice brains.

Jiang, H., Gao, H., Kong, J., Song, B., Wang, P., Shi, B., ... & Li, Z. (2018). Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research, 6(11), 1314-1326.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFR (7B3) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP8038). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.